Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Marta Kovatcheva, PhD

Principal Investigator, Clle Plasticity and Agining, IFOM

Share

Share

Marta Kovatcheva

Lab Phone

212-639-2354

Email

[email protected]

Dissertation

New roles for old proteins: MDM2 and ATRX drive the transition from quiescence to senescence (2017)

Mentor

Andrew Koff, PhD

Start Year

2010

End Year

2017

Education

University of Toronto

Fellowships

Grayer Fellowship (2012-2013)

Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship (2011-2012)

Publications

Kovatcheva M, Klein ME, Tap WD, Koff A. (2017) Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol. 5, e1384882. PMCID: PMC5791849. [Available on 2018-11-07]

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. (2018) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. [Epub ahead of print]

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A. (2017) ATRX is a regulator of therapy induced senescence in human cells. Nat Commun. 8, 386. PMCID: PMC5577318

Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, Koff A. (2015) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 6, 8226-43. PMCID: PMC4480747.

View a full listing of Marta Kovatcheva’s journal articles.